NCT04317729View on ClinicalTrials.gov

DBS Evaluation of Fujirebio INNOTEST® HCV Ab IV

NACompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

January 30, 2020

Primary Completion Date

April 30, 2020

Study Completion Date

May 31, 2020

Conditions
Hepatitis C Virus Infection
Interventions
DEVICE

Fujirebio INNOTEST® HCV Ab IV assay

Enzyme Immunoassay

Trial Locations (2)

79000

Astar Medical Centre, Lviv

79026

Lviv Regional Public Health Centre, Lviv

All Listed Sponsors
lead

Foundation for Innovative New Diagnostics, Switzerland

OTHER

NCT04317729 - DBS Evaluation of Fujirebio INNOTEST® HCV Ab IV | Biotech Hunter | Biotech Hunter